Clinical Trial Update: Validation of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) Prognostic Classification for Targeted Therapies (TKI/mTOR Inhibitors) in Second Line After First Line Treatment With Pazopanib

View source ↗

Summary

Completed clinical trial validating the IMDC prognostic classification for second-line therapy in metastatic renal cell carcinoma after initial pazopanib treatm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Pazopanib (Votrient) (Pazopanib)

Snippet

Sponsor: Spanish Oncology Genito-Urinary Group | Conditions: Metastatic Renal Cell Carcinoma | Status: COMPLETED